论文部分内容阅读
目的:观察孟鲁司特联合常规治疗哮喘患儿的疗效及对血清金属蛋白酶-9(MMP-9)及其抑制因子-1(TIMP-1)水平的影响。方法:90例哮喘患儿随机分为对照组和观察组各45例。对照组予哮喘常规对症支持治疗,观察组在对照组基础上加用孟鲁司特咀嚼片,两组疗程均为8周。比较两组临床疗效与药品不良反应,观察两组患儿治疗前后肺功能指标及血清MMP-9、TIMP-1水平的变化。结果:观察组临床总有效率为93.33%,明显优于对照组(P<0.05)。治疗后,两组患儿的FEV1及PEF均较治疗前显著升高(P<0.05),血清MMP-9、TIMP-1水平则较前显著降低(P<0.05),且观察组各项指标均明显优于对照组(P<0.05)。两组患儿均未见药品不良反应发生。结论:孟鲁司特联合常规治疗可下调支气管哮喘患儿血清MMP-9、TIMP-1水平,抑制气道重塑,提高疗效,且安全性高,值得临床推广。
Objective: To observe the effects of montelukast combined with routine treatment on children with asthma and its effect on serum levels of metalloproteinase-9 and its inhibitor of metalloproteinase-1 (TIMP-1). Methods: 90 asthmatic children were randomly divided into control group and observation group of 45 cases. The patients in the control group were given conventional symptomatic and supportive treatment of asthma. The observation group was given montelukast chewable tablets on the basis of the control group. The two courses of treatment were 8 weeks. The clinical efficacy and adverse drug reactions were compared between the two groups. The changes of pulmonary function indexes, serum MMP-9 and TIMP-1 levels in both groups before and after treatment were observed. Results: The total clinical effective rate in the observation group was 93.33%, which was significantly better than that in the control group (P <0.05). After treatment, the FEV1 and PEF in both groups were significantly higher than those before treatment (P <0.05), and the levels of serum MMP-9 and TIMP-1 were significantly lower than those before treatment (P <0.05) Were significantly better than the control group (P <0.05). No adverse reactions occurred in both groups of children. Conclusion: Montelukast combined with conventional treatment can down-regulate serum MMP-9 and TIMP-1 in bronchial asthma, restrain airway remodeling and improve the curative effect, which is safe and worthy of clinical promotion.